NLSP Overview

DOXA Platform Expansion: NLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, focusing on small molecules that enhance arousal stability, cognition, and neuroprotection.

Lead Compound AEX-635: AEX-635, a key compound in the DOXA series, targets Multidrug Resistance-Associated Protein 1 (MRP1) to improve neuroprotective effects and drug bioavailability in conditions like Parkinson's disease.

Merger Announcement: NLS Pharmaceutics Ltd. and Kadimastem Ltd. have received Nasdaq approval for their merger, with the closing date set for October 30, 2025, and Kadimastem's shares to be delisted from the Tel Aviv Stock Exchange on October 31, 2025.

Share Exchange Ratio: The final exchange ratio for the merger is established at 7.06 NLS common shares for each Kadimastem ordinary share, which will adjust to 0.706 NLS common shares after a reverse share split.

New Company Formation: The merged entity will be named NewCelX Ltd. and will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025.

Forward-Looking Statements: The announcement includes forward-looking statements regarding the merger's completion and trading timelines, highlighting potential risks and uncertainties that could affect the expected outcomes.

Reverse Share Split Announcement: NLS Pharmaceutics Ltd. plans to implement a 1-for-10 reverse share split of its common shares, effective October 30, 2025, coinciding with its merger with Kadimastem Ltd.

New Trading Symbol and Name: Following the reverse split and merger, the company's shares will trade under the new symbol "NCEL" and the new name "NewcelX Ltd." starting October 31, 2025.

Share Capital Structure Post-Merger: After the reverse split and merger, the company will have approximately 4.56 million outstanding common shares and a revised capital structure, including preferred shares and participation certificates.

Fractional Shares and Adjustments: No fractional shares will be issued due to the reverse split; instead, cash will be provided for any resulting fractions, and all existing options and warrants will be adjusted accordingly.

Merger Announcement: NLS Pharmaceutics and Kadimastem have signed a Memorandum of Understanding to collaborate under the new company, NewCelX, following their anticipated merger.

Focus on Advanced Therapies: The partnership aims to enhance the development of innovative therapies for severe diseases, leveraging Kadimastem's cell therapy solutions and TargetGene's precision gene-editing technologies.

Merger Announcement: NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced an update regarding their proposed merger, aimed at enhancing their capabilities in treating CNS disorders and neurodegenerative diseases.

Company Profiles: NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company, while Kadimastem is an advanced clinical-stage cell therapy company focused on neurodegenerative diseases and diabetes.

Merger Approval: NLS Pharmaceutics Ltd. shareholders have approved the merger with Kadimastem Ltd., clearing the final corporate hurdle for the formation of NewCelX Ltd.

Future Plans: The combined company is set to be listed on Nasdaq under the ticker "NCEL," pending final approval, marking a significant step in establishing a transatlantic biopharma leader.